{"id":"recombivax-hb-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the introduction of the hepatitis B surface antigen and core antigen, which triggers the body's immune system to produce antibodies and immune cells that can recognize and attack the virus.","oneSentence":"Recombivax HB vaccine stimulates an immune response to the hepatitis B virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:19.281Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in adults and children"}]},"trialDetails":[{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT04456504","phase":"PHASE4","title":"HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-09-15","conditions":"Healthcare Worker, Hepatitis B Vaccine, Nonresponder","enrollment":49},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT02429583","phase":"PHASE4","title":"Effects of Persistent Innate Immune Activation on Vaccine Efficacy","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2015-05-08","conditions":"Hepatitis C Infection","enrollment":24},{"nctId":"NCT04162223","phase":"EARLY_PHASE1","title":"Hepatitis B Vaccine in Seniors","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2000-03-29","conditions":"Hepatitis B Vaccination","enrollment":52},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01463683","phase":"PHASE3","title":"Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-29","conditions":"Hepatitis B","enrollment":722},{"nctId":"NCT02055365","phase":"NA","title":"Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2014-02-18","conditions":"Hepatitis B","enrollment":10},{"nctId":"NCT00414050","phase":"PHASE3","title":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Hepatitis B","enrollment":1718},{"nctId":"NCT00440531","phase":"PHASE3","title":"Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":"Hepatitis B","enrollment":540},{"nctId":"NCT00393523","phase":"PHASE3","title":"Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hepatitis B","enrollment":1478},{"nctId":"NCT00107042","phase":"PHASE2","title":"Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2004-02","conditions":"Hepatitis B","enrollment":123},{"nctId":"NCT00322361","phase":"PHASE2","title":"Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Hepatitis B, Hepatocellular Carcinoma","enrollment":566},{"nctId":"NCT00489099","phase":"PHASE3","title":"A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":"Hepatitis B Infection","enrollment":860},{"nctId":"NCT00142753","phase":"PHASE4","title":"Immunologic Memory (Supp. of ATN 024)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-08","conditions":"HIV Infections","enrollment":95},{"nctId":"NCT02057263","phase":"PHASE1","title":"The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Hepatitis B","enrollment":28},{"nctId":"NCT00551915","phase":"PHASE2","title":"A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-05","conditions":"Bacterial Infections; Virus Diseases","enrollment":756},{"nctId":"NCT02040636","phase":"PHASE2","title":"Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"1999-01","conditions":"Pertussis, Tetanus, Diphtheria","enrollment":277}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Recombivax HB vaccine","genericName":"Recombivax HB vaccine","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Recombivax HB vaccine stimulates an immune response to the hepatitis B virus. Used for Prevention of hepatitis B infection in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}